Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation.
Cytokines including IL-6 and TNF-alpha play an important role in the pathogenesis of postmenopausal osteoporosis. However, the relationship between changes in the cytokine levels and subsequent bone loss in patients undergoing a bone marrow transplantation (BMT) is unclear. A total of 46 patients undergoing an allogeneic BMT were prospectively investigated. The bone turnover markers and the serum cytokines were measured before BMT and serially after BMT. Bone mineral density (BMD) was measured before and 1 year after BMT. At 1 year after BMT, the lumbar spine BMD had decreased by 4.8%, and the total proximal femoral BMD had decreased by 12.3%. The serum IL-6 and TNF-alpha levels increased until 2 and 3 weeks after BMT, respectively. The lumbar BMD was significantly decreased as the serum IL-6 and TNF-alpha levels increased by post-BMT 3 weeks. The lumbar BMD decreased significantly as the cumulative prednisolone and cyclosporine dose increased. Patients with GVHD > or =grade II had higher lumbar bone loss than patients with GVHD <grade I. In conclusion, immunosuppressants, GVHD occurrence and increase in bone-resorbing cytokines in the early post-BMT period were associated with later bone loss after BMT. Further studies are needed to elucidate the precise mechanism.
Lee
W-Y
WY
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Baek
K-H
KH
Rhee
E-J
EJ
Tae
H-J
HJ
Oh
K-W
KW
Kang
M-I
MI
Lee
K-W
KW
Kim
S-W
SW
Kim
C-C
CC
Oh
E-S
ES
D000328:Adult; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D001862:Bone Resorption / Q000139:chemically induced / Q000209:etiology*; D015331:Cohort Studies; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood / Q000502:physiology*; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D015415:Biomarkers; D016207:Cytokines; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D011239:Prednisolone